Nakajima Y - Search Results

1

The in vitro cross-reactivity and blood coagulation potential of recombinant porcine factor VIII in Japanese patients with acquired hemophilia A.

Takeyama M, Sasai K, Miyaguchi Y, Ogiwara K, Furukawa S, Shimonishi N, Nakajima Y, Ueda H, Nogami K. Takeyama M, et al. Among authors: nakajima y. Int J Hematol. 2024 Oct 30. doi: 10.1007/s12185-024-03854-5. Online ahead of print. Int J Hematol. 2024. PMID: 39476173

2

Evaluation of clinical severity in patients with type 2N von Willebrand disease using microchip-based flow-chamber system.

Nakajima Y, Nogami K, Yada K, Kawamura T, Ogiwara K, Furukawa S, Shimonishi N, Takeyama M, Shima M. Nakajima Y, et al. Int J Hematol. 2020 Mar;111(3):369-377. doi: 10.1007/s12185-019-02782-z. Epub 2019 Nov 18. Int J Hematol. 2020. PMID: 31741138

3

Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor.

Nakajima Y, Tonegawa H, Noguchi-Sasaki M, Nogami K. Nakajima Y, et al. Int J Hematol. 2021 Jun;113(6):789-796. doi: 10.1007/s12185-021-03108-8. Epub 2021 Feb 26. Int J Hematol. 2021. PMID: 33635530

4

Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concentrations of Emicizumab in Patients with Acquired Hemophilia A.

Takeyama M, Furukawa S, Yada K, Ogiwara K, Shimonishi N, Nakajima Y, Mizumachi K, Noguchi-Sasaki M, Shima M, Nogami K. Takeyama M, et al. Among authors: nakajima y. Thromb Haemost. 2021 Oct;121(10):1289-1298. doi: 10.1055/s-0041-1725009. Epub 2021 Feb 28. Thromb Haemost. 2021. PMID: 33641138

5

Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients.

Nakajima Y, Mizumachi K, Shimonishi N, Furukawa S, Yada K, Ogiwara K, Takeyama M, Shima M, Nogami K. Nakajima Y, et al. Int J Hematol. 2022 Apr;115(4):489-498. doi: 10.1007/s12185-021-03276-7. Epub 2022 Jan 19. Int J Hematol. 2022. PMID: 35043383

6

The balance of comprehensive coagulation and fibrinolytic potential is disrupted in patients with moderate to severe COVID-19.

Onishi T, Shimonishi N, Takeyama M, Furukawa S, Ogiwara K, Nakajima Y, Kasahara K, Nishio K, Yoshimoto K, Inoue S, Kawaguchi M, Fukushima H, Saito Y, Yoshiji H, Muro S, Tsuruya K, Okada S, Sugie K, Kawaguchi R, Nishikubo T, Yamazaki M, Oda Y, Kawabe T, Onishi K, Nishio T, Nogami K. Onishi T, et al. Among authors: nakajima y. Int J Hematol. 2022 Jun;115(6):826-837. doi: 10.1007/s12185-022-03308-w. Epub 2022 Feb 16. Int J Hematol. 2022. PMID: 35171446 Free PMC article.

7

A case of a young boy with hyper-fibrinolysis associated with natural fibrin precipitates suspected to have occurred through a novel coagulation and fibrinolysis mechanism.

Nishiyama A, Ogiwara K, Nakajima Y, Furukawa S, Matsumoto T, Takeda H, Nogami K. Nishiyama A, et al. Among authors: nakajima y. Int J Hematol. 2022 Aug;116(2):276-287. doi: 10.1007/s12185-022-03339-3. Epub 2022 Apr 13. Int J Hematol. 2022. PMID: 35416587

8

Two pediatric cases of severe hemophilia A in which emicizumab prophylaxis failed to prevent traumatic extra-articular hemorrhage.

Yamada Y, Nakajima Y, Ohara A, Wakita E, Shimizu K, Shimonishi N, Furukawa S, Ogiwara K, Takeyama M, Nogami K. Yamada Y, et al. Among authors: nakajima y. Int J Hematol. 2023 Apr;117(4):607-612. doi: 10.1007/s12185-022-03490-x. Epub 2022 Nov 12. Int J Hematol. 2023. PMID: 36370317 Free PMC article.

9

High levels of factor VIII activity in patients with acquired hemophilia A in remission are associated with unusually low coagulation potentials.

Shibasaki F, Takeyama M, Ogiwara K, Furukawa S, Nakajima Y, Shimonishi N, Nogami K. Shibasaki F, et al. Among authors: nakajima y. Int J Hematol. 2023 May;117(5):669-677. doi: 10.1007/s12185-022-03528-0. Epub 2023 Jan 6. Int J Hematol. 2023. PMID: 36607560

10

Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis.

Shimonishi N, Sasai K, Ogiwara K, Furukawa S, Nakajima Y, Mizumachi K, Yada K, Takeyama M, Shima M, Mizuno N, Nogami K. Shimonishi N, et al. Among authors: nakajima y. Int J Hematol. 2023 Dec;118(6):690-698. doi: 10.1007/s12185-023-03667-y. Epub 2023 Oct 6. Int J Hematol. 2023. PMID: 37803190

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,671 results

Search Page

Filters